Clinical trial
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty…
NCT00167310 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00167310 |
|---|---|
| Title | Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation |
| Official title | CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation |
| Acronym | CAD |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | American Heart Association VA Pittsburgh Healthcare System U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | Eicosapentaenoic acid (omega-3 fatty acid), Placebo |
| Enrollment | 57 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2015 |
| Completion | Dec 1, 2015 |
| First posted | Sep 14, 2005 |
| Last update posted | Apr 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: